AHA 2020 – look out for the omecamtiv fault lines

Hopes that a subgroup benefit might point a way forward for Amgen/Cytokinetics’ heart failure project omecamtiv mecarbil have taken a knock. Full data from the Galactic-HF study, unveiled on Friday at the American Heart Association meeting, confirmed the worst fears, and omecamtiv looks dead in the water.